ImmuneOnco Biopharmaceuticals (Shanghai) Applies for Phase III Clinical Trial Approval of IMM0306 for Follicular Lymphoma in China (Note: There is no indication of grant/funding or involvement of multiple organizations in the provided announcement; the news is about a regulatory application for a Phase III clinical trial.)
**ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. Submits Phase III Clinical Trial Application for IMM0306 in Follicular Lymphoma** ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. has announced that it has submitted an application to the Center for Drug Evaluation of the National Medical Products Administration (NMPA) of China for a Phase III clinical trial of its investigational therapy, IMM0306, for the treatment of follicular lymphoma. IMM0306 is a first-in-class bispecific molecule targeting both CD47 and CD20, designed to enhance immune-mediated elimination of malignant B cells while minimizing toxicity. The company currently retains global intellectual property and commercial rights to IMM0306. No grant or funding from other organizations was mentioned in the announcement. The company cautioned that there is no guarantee of successful development or commercialization of the drug.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。